Cel-Sci Corp. (CVM)
XASE:CVM
Want to see CVM full AI Analyst Report?
CVM Stock Chart & Stats
$5.19
-$0.03(-7.92%)
At close: 4:00 PM EST
$5.19
-$0.03(-7.92%)
Day’s Range― - ―
52-Week Range$1.98 - $13.48
Previous Close$0.36
Volume1.47M
Average Volume (3M)125.69K
Market Cap
$19.28M
Enterprise Value$24.35M
Total Cash (Recent Filing)$6.28M
Total Debt (Recent Filing)$10.63M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding8,457,967
10 Day Avg. Volume66,836
30 Day Avg. Volume125,686
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap1.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.32
Enterprise Value/Ebitda-1.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Contract Manufacturing CapabilityCEL‑SCI’s GMP contract development and manufacturing capability provides durable fee‑based revenue potential beyond equity raises. Specialized cell and gene bioprocessing can secure multi‑period client contracts, monetize existing assets, and build industry partnerships that help stabilize cash flow over time.
Narrowing Net LossesMulti‑year reduction in net losses indicates improving expense control and operational discipline. Narrower losses reduce near‑term financing pressure, extend clinical development runway without immediate dilution, and signal management focus on cost efficiency that can materially affect sustainability over several quarters.
More Moderate Trailing LeverageTrailing‑twelve‑month balance metrics showing moderate debt/equity and sizable equity suggest the company may have more financial flexibility than the 2025 annual outlier implies. A healthier TTM capital structure supports operational continuity, contract business scaling, and lowers immediate solvency risk while trials progress.
Bears Say
Pre-revenue, Persistent Cash BurnCEL‑SCI remains a pre‑revenue, clinical‑stage biotech with sustained negative operating results and ongoing cash burn. Without product sales, the company depends on external financing and contract services; this structural funding need increases dilution risk and makes long‑term planning contingent on successful trials or steady service contracts.
Extreme Cash-flow Outlier In 2025An extraordinarily large reported operating cash outflow in 2025 materially departs from multi‑year patterns and undermines cash‑flow reliability. Whether a one‑time adjustment or reporting anomaly, it complicates liquidity forecasting, raises questions for creditors/partners, and increases structural funding uncertainty over coming quarters.
2025 Balance-sheet Leverage OutlierThe 2025 annual report showing massive debt and an extreme debt/equity ratio, versus prior modest debt levels, either signals a catastrophic financing event or a data/reporting anomaly. In either case, it elevates long‑term refinancing, covenant and solvency risk, and undermines stakeholder confidence in financial stability.
Cel-Sci News
CVM FAQ
What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was $1.98 and its highest was $13.48 in the past 12 months.
What is Cel-Sci Corp.’s market cap?
Cel-Sci Corp.’s market cap is $19.28M.
When is Cel-Sci Corp.’s upcoming earnings report date?
Cel-Sci Corp.’s upcoming earnings report date is May 14, 2026 which is in 10 days.
How were Cel-Sci Corp.’s earnings last quarter?
Cel-Sci Corp. released its earnings results on Feb 18, 2026. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.68.
Is Cel-Sci Corp. overvalued?
According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued.
Does Cel-Sci Corp. pay dividends?
Cel-Sci Corp. does not currently pay dividends.
What is Cel-Sci Corp.’s EPS estimate?
Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-Sci Corp. have?
Cel-Sci Corp. has 8,457,967 shares outstanding.
What happened to Cel-Sci Corp.’s price movement after its last earnings report?
Cel-Sci Corp. reported an EPS of -$0.68 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.368%.
Which hedge fund is a major shareholder of Cel-Sci Corp.?
Currently, no hedge funds are holding shares in CVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cel-Sci Corp.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Technical Analysis
Ownership Overview
2.55% Insiders
3.70% Mutual Funds
<0.01% Other Institutional Investors
90.95% Public Companies and
Individual Investors